血管生成抑制剂治疗结肠癌肝转移的研究进展
被引量：1
The development of angiogenesis inhibitors in treating hepatic metastasis of colon cancer
摘要
血管生成抑制剂与传统的细胞毒化疗药物不同 ,可作用于包含多种变异的正常细胞。因此 ,血管生成抑制剂与细胞毒药物临床应用的传统策略不同。许多临床研究正在用一种新的途径评价这些涉及到抑制细胞生长繁殖不同时期的药物。
出处
《国外医学（肿瘤学分册）》
2002年第3期228-231,共4页
Foreign Medical Sciences (Cancer Section)
参考文献19
-
1Pritchard KI. Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optinum therapeutic management[J]? Eur J Cancer, 1997,33(suppl 7):S11-14.
-
2Singh RK,TsanR, Radinsky R. Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis [J]. Clin Exp Metastasis, 1997,15(2):140-150.
-
3Lieken S, De Clercq E, Neyts J. Angiogenesis regulators and clinical applications[J]. Biochem Pharmacol,2001,61(3):253-270.
-
4Sedlakova O, Sedlak J, Hunakovo L, et al. Angiogene-sis inhibitor TNP-470:cytoxic effects on human neoplastic cell lines[J]. Neoplasma, 1999,46(5):283-289.
-
5Turk BE,Griffith EC,Wolf S, et al. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells[J]. Chem Biol, 1999,6 (11):823-833.
-
6Arasteh K, Hannah A. The role of vascular endothelial cell growth factor(VEGF) in AIDS-related Kaposi's sarcoma[J]. Oncol, 2000,5(Suppl 1):28-31.
-
7Mendel DB, Laird AD,Smolich BD, et at. Development of SU5416,a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent [J]. Anticancer Drug Des, 2000,15(1):29-41.
-
8Via LE,Gore Langton RE, Pluda JM. Clinical trials referral resounce. Current clinical trials administering the antiangiogenesis agent SU5416[J]. Oncology(Huntingt), 2000,14(9):1312,1315-1316.
-
9Fong TA, Shawver LK, Sun LJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth faetor(FIK-1/KDR) that inhibits tyrosine kinase catalysis, tumor vaseularization, and growth of multiple tumor types[J]. Cancer Res, 1999, 59 (1):99-106.
-
10Rowinsky EK, Humphrey R, Hammond LA, et al. Phase land pharmacolgic study of the specific matrix metalloproteinase inhibitor BAY12-9566 on protracted oral daily dosing schedule in patients with solid malignancies[J]. J Clin Oneo1,2000,18(1):178-186.
同被引文献5
-
1Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 1996, 77(5):858
-
2何永文,赵德萍,刘流,贾伟,谢春,李坚,黎明.高温诱导颊癌细胞凋亡的相关机理研究[J].口腔医学纵横,2001,17(1):12-14. 被引量：9
-
3孙立群,杨桂琴,王宗贵,辛丁,管国芳,王银玉.抗人喉癌/抗蓖麻毒素A双功能抗体制备及细胞毒活性研究[J].耳鼻咽喉（头颈外科）,2002,9(1):36-38. 被引量：2
-
4何小鹃,李官成.肿瘤基因工程抗体研究进展[J].国外医学（肿瘤学分册）,2002,29(4):245-248. 被引量：3
-
5张庆元,李金荣,李武修,吴淑华,吕增华,孙小云.口腔鳞状细胞癌血管内皮细胞生长因子的表达[J].实用口腔医学杂志,2003,19(4):362-365. 被引量：7
-
1管增伟,王盛兰,李勇.半胱氨酸蛋白酶与细胞凋亡[J].国外医学（肿瘤学分册）,2000,27(5):280-282. 被引量：16
-
2张康,左强,罗荣城.吉非替尼治疗36例晚期非小细胞肺癌[J].中国癌症杂志,2006,16(10):878-879. 被引量：15
-
3Jeffrey,A.Meyerhardt,M.P.H,Robert,J.Mayer,杨昌山.结直肠癌的系统治疗[J].中国处方药,2005(10):23-25. 被引量：3
-
4高新丽.肿瘤患者化学药物治疗的护理[J].山西医药杂志（下半月）,2008,37(6):565-566. 被引量：3
-
5余平,刘晓旺,钟丽菲,丁维珂,陆凯强,周志刚,涂剑.低氧微环境相关因子HIF-1α与癌症的研究[J].湖南生态科学学报,2015,2(2):52-56. 被引量：6
-
6蔡浩权,林英城.不可切除转移性结直肠癌的治疗策略[J].国际肿瘤学杂志,2012,39(10):775-778. 被引量：3
-
7李淑敏,章文华.贝伐单抗在卵巢上皮性癌化疗中的应用进展[J].中华妇产科杂志,2009,44(6):475-477. 被引量：1
-
8郑华金,袁良平.自体骨髓移植在恶性血液病和实体瘤中的应用[J].西南国防医药,1994,4(6):371-373.
-
9于中国.肿瘤患者化疗期间应注意什么?[J].中老年保健,2014(3):43-43.
-
10温焕连,王晨龙,曾文铤,朱科伦.三氧化二砷与顺铂联用对肝癌HepG2细胞的作用[J].广东医学,2007,28(12):1902-1904. 被引量：6
